Monoallelic germline mutations in the BRCA1 and BRCA2 confer high life‐time risks for breast cancer (BC) and ovarian cancer (OC) (Kuchenbaecker et al., 2017) and were found in approximately 24% of index patients who met the inclusion criteria of the German Consortium for Hereditary Breast and Ovarian Cancer (GC‐HBOC) for germline testing (Kast et al., 2016). Here, BRCA2 is linked to breast cancer.